Startseite Facile synthesis of substituted dihydro-1H-pyrazolo[3,4-d]thiazoles through enaminones of 4-thiazolidinones
Artikel Open Access

Facile synthesis of substituted dihydro-1H-pyrazolo[3,4-d]thiazoles through enaminones of 4-thiazolidinones

  • Poonam Gautam und R. P. Chaudhary EMAIL logo
Veröffentlicht/Copyright: 14. Juni 2014

Abstract

A short two-step synthesis of substituted dihydro-1H-pyrazolo[3,4-d]thiazoles from 4-thiazolidinones is described. 4-Thiazolidinones are easily synthesized by the reaction of thiosemicarbazones of carbonyl compounds and chloroacetic acid. Upon treatment with Lawesson’s reagent and dimethylformamide-dimethylacetal, 5-dimethylaminomethylene-3-methylthiazolidine-4-thiones are formed, which undergo condensation with hydrazine derivatives to furnish substituted dihydro-1H-pyrazolo[3,4-d]thiazoles. The structure of the synthesized compounds was established by elemental analysis and analysis of spectral data.

Introduction

Heterocyclic compounds occupy a prominent place in medicinal chemistry as pharmaceutical and drug intermediates. Nearly 70% of all commercially available agrochemicals and pharmaceuticals are heterocyclic compounds. Pyrazole derivatives have been the focus of increasing attention owing to their numerous pharmacological applications and biological activities such as antimicrobial [1, 2], antiviral [3, 4], antitumor [5], and anti-inflammatory [6] properties. The pyrazole moiety is utilized within the core structure of various drugs such as diferanizole, celecoxib, and tepoxalin, among others. Most of these active compounds bear either one or more heterocyclic scaffolds or a benzannulated bicyclic core. There are only a few known active bicyclic scaffolds which are made up of two different heterocycles. Examples include imidazothiazole anthelmintics, such as levamisole and allopurinol, and a purine analog, xanthine oxidase (XO) inhibitor, used in the treatment of gout and hyperuricemia. Condensed pyrazoles are known for various biological activities, for example, pyrazolo[3,4-b]quinolines are potential antiviral [7] and antimalarial [8] agents, pyrazolo[4,3-c]quinolines are antiangiogenic [9] compounds, pyrazolo[3,4-c]pyrimidine are antitumor [10] agents, pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidin-4-ones are XO inhibitors [11], and pyrazolo[1,5-a]pyrimidines are cytotoxic agents [12].

In view of the above biological importance and in continuation of our studies on the synthesis and characterization of novel 4-thiazolidinone [13–15] and pyrazole derivatives, here we report facile synthesis of fused pyrazolo[3,4-d]thiazoles from enaminones of 4-thiazolidinones.

Results and discussion

A two-step synthesis of a pyrazolo[3,4-d]thiazole system from a thiazolidinone is described. The first step of the general approach involves the conversion of thiazolidinone 1 into its arylidene derivative 2 via Claisen condensation with an aldehyde. In the second step, condensation of 5-arylidenethiazolidinones [16, 17] with different hydrazine derivatives was attempted to furnish the desired tetrahydropyrazolo[3,4-d]thiazoles 3 (Scheme 1). Unfortunately, our several attempts by using acidic and basic reagents (acetic acid, sodium acetate, piperidine) and different solvents (methanol, trifluoroethanol, acetonitrile, tetrahydrofuran) did not bring about the desired ring closure reaction. The reaction of the arylidene derivative 2 with hydrazine hydrate produced compound 4 (Scheme 1), which was identified on the basis of its 1H NMR and mass spectral data. 1H NMR spectrum of 4 exhibits one multiplet of two protons and two triplets of two protons each at δ 1.93, 2.78, and 2.85, respectively, which are assigned to the tetrahydronaphthalene moiety. Mass spectrum of 4 exhibits an intense peak at m/z 289.2 for [M+H] (100%).

Scheme 1
Scheme 1

The synthesis of hydrazono-thiazolidinone 1 bearing the tetrahydronaphthalene moiety has been reported in our previous communication [18] by using a conventional method as well as synthesis in ionic liquid. The reaction of thiazolidinone 1 with dimethylformamide-dimethylacetal furnished enaminone 5. It was found that in addition to the condensation of the active methylene function of thiazolidinone at position 5 with dimethylformamide-dimethylacetal, methylation of a cyclic amide function (CONH) also occurs during this reaction. Similar hydrazono-dihydropyrazolo[3,4-d]thiazoles have been obtained previously by condensation of an α-hydroxynitrile [19–21] and 5-α-amino-β-trichloroethanylidino-4-oxothiazole [22] with hydrazine derivatives. In this study, we attempted the synthesis of pyrazolo[3,4-d]thiazoles from thiazolidinone enaminone 5 and hydrazines using different basic reagents such as sodium acetate, pyridine, and piperidine. Unfortunately, ring closure was not achieved. Recently, Pelletier et al. [23] have reported the synthesis of tetrahydropyrazolo[3,4-d]thiazole by condensation of 5-benzylidene-4-thiazolidine-thione with hydrazines by enhancing the reactivity of thiazolidinone through thionation of the lactam function. Using a similar approach, we converted thiazolidin-4-one 1 into 4-thiazolidin-thione 6. This transformation was easily carried out with Lawesson’s reagent [24]. The reaction of enaminone 5 with Lawesson’s reagent in toluene furnished corresponding 4-thiazolidine-thiones 6. The reaction of thiazolidinone 1 with dimethylformamide-dimethylacetal and then conversion of enaminone 5 into the thione derivative 6 could also be achieved in a single step. Thiazolidinone 1 was first heated under reflux with Lawesson’s reagent in toluene and then the mixture was treated with dimethylformamide-dimethylacetal under continuing reflux conditions for an additional 60 min to give the same thione derivative 6. The reaction of 4-thiazolidin-thione 6 with hydrochloride salts of different hydrazines in ethanol furnished pyrazolo[3,4-d]thiazoles 7 (Scheme 2). The structures of the synthesized compounds were established by elemental analysis, IR, 1H NMR, 13C NMR, and mass spectral data. It should be noted that the products can exist in a number of geometrical isomers. In all cases, the TLC analysis indicated the presence of a single diastereomer but stereochemistry was not investigated.

Scheme 2 Reagents and conditions: (a) DMF-DMA, DMF, reflux; (b) R2NHNH2·HCl, EtOH, stirring at 80°C; (c) Lawesson’s reagent, toluene, reflux; (d) Lawesson’s reagent, toluene, DMF-DMA. DMF-DMA, dimethylformamide-dimethylacetal.
Scheme 2

Reagents and conditions: (a) DMF-DMA, DMF, reflux; (b) R2NHNH2·HCl, EtOH, stirring at 80°C; (c) Lawesson’s reagent, toluene, reflux; (d) Lawesson’s reagent, toluene, DMF-DMA. DMF-DMA, dimethylformamide-dimethylacetal.

Conclusion

A general synthesis of dihydro-1H-pyrazolo[3,4-d]thiazoles from 4-thiazolidinones was achieved in two simple steps. In the first step, 5-dimethylaminomethylene-3-methylthiazolidine-4-thiones were obtained by the reaction of thiazolidinones with Lawesson’s reagent and dimethylformamide-dimethylacetal. The ring construction of the second step was accomplished by treatment with hydrazine derivatives in acidic medium.

Experimental

All chemicals were obtained from Sigma and used without further purification. Melting points were determined in open capillaries and are uncorrected. Elemental analysis was done on a Euro EA 3000 elemental analyzer. Mass spectra were recorded on a Waters, Q-TOF Micromass, LC-MS instrument. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded in CDCl3 on a Bruker Avance II 400 spectrometer using tetramethylsilane (TMS) as an internal standard. IR spectra were recorded on an Abb FTIR spectrometer. Thin layer chromatography (TLC) was performed on silica gel G-coated plates and using iodine vapor as a visualizing agent. Thiazolidin-4-ones 1a,b were obtained by cyclocondensation of thiosemicarbazone of 1-tetralone and chloroacetic acid, as reported previously [18].

{5-Benzylidene-2-[3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}thiazolidin-4-one (2)

A mixture of thiazolidin-4-one 1 (0.5 mmol), benzaldehyde (0.5 mmol), and sodium ethoxide (0.02 g of sodium in 2.0 mL of absolute ethanol) in dry benzene (20 mL) was heated under reflux for 10–12 h. The progress of the reaction was monitored by TLC. After completion, the mixture was cooled and poured into ice-cold water. The organic layer was dried over fused calcium chloride and concentrated under reduced pressure. The residue of 2a was crystallized from ethanol: orange crystalline solid; yield 62%; mp 180–182°C; IR (cm-1): 1697 (C=O), 1605 (C=N); 1H NMR: δ 1.90–1.96 (m, 2H, CH2), 2.85 (t, 2H, CH2, J = 6 Hz), 2.94 (t, 2H, CH2, J = 6 Hz), 7.18 (d, 1H, C6H5, J = 7 Hz), 7.29–7.34 (m, 2H, C6H5), 7.36–7.39 (m, 1H, C6H5), 7.48–7.55 (m, 2H, C6H5), 7.61 (d, 2H, C6H5, J = 7 Hz), 7.71 (s, 1H, =CH), 8.32 (d, 1H, C6H5, J = 7 Hz), 8.82 (br, 1H, NH). Anal. Calcd for C20H17N3OS: C, 69.14; H, 4.93; N, 12.09; S, 9.23. Found: C, 69.33; H, 5.12; N, 12.32; S, 9.40.

Attempted synthesis of 5-{[3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-2,3-diphenyl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d]thiazole (3)

A mixture of compound 2 (0.5 mmol), phenylhydrazine (0.75 mmol), and anhydrous sodium acetate (1.0 mmol) in ethanol (25 mL) was heated under reflux for 20–24 h. The progress of the reaction was monitored by TLC. There was no change after 24 h. This attempted reaction was tried under acidic (acetic acid) and basic conditions (piperidine, sodium acetate). Unfortunately, the reaction did not happen and the starting material was obtained in all cases.

1-[3,4-Dihydronaphthalen-1(2H)-ylidene]-2-[3,4-dihydronaphthalen-2(1H)-ylidene]hydrazine (4)

Equimolar mixture of compound 2 and hydrazine hydrate (98%) in ethanol was heated under reflux for 8 h. Excess ethanol was distilled off and the solid obtained on cooling was crystallized from ethanol-DMF (3:1) mixture: light green solid; yield 60%; mp 118–120°C; 1H NMR: δ 1.89–1.96 (m, 2H, CH2), 2.78 (t, 2H, CH2, J = 6 Hz), 2.84 (t, 2H, CH2, J = 6 Hz), 7.17 (d, 1H, C6H5, J = 7 Hz), 7.28–7.31 (m, 2H, C6H5), 8.31 (d, 1H, C6H5, J = 7 Hz); MS: m/z 289.2 (M+H)+ (100%).

General procedure for the synthesis of 5

A mixture of thiazolidin-4-one 1 (1.0 mmol) and dimethylformamide-dimethylacetal (10 mmol) in dimethylformamide (5.0 mL) was heated under reflux for 50 min, then cooled and extracted with ethyl acetate (2 × 25 mL). The extract was washed with brine and dried over anhydrous Na2SO4. The excess ethyl acetate was then removed under reduced pressure and the solid obtained was filtered and crystallized from ethanol.

2-{[3,4-Dihydronaphthalen-1(2H)-ylidene]hydrazono}-5-[(dimethylamino)methylene]-3-methylthiazolidin-4-one (5a)

Light brown crystals; yield 82%; mp 206–208°C; IR (cm-1): 1697 (C=O), 1556 (C=N), 1490 (C=C); 1H NMR: δ 1.89–1.96 (m, 2H, CH2), 2.82 (t, 2H, CH2, J = 6 Hz), 2.98 (t, 2H, CH2, J = 6 Hz), 3.16 (s, 6H, NMe2), 3.36 (s, 3H, N-CH3), 7.13–7.15 (m, 1H, C6H5), 7.20–7.29 (m, 2H, C6H5), 7.45 (s, 1H, =CH), 8.26 (dd, 1H, C6H5, J = 1.5 Hz, J = 6 Hz). Anal. Calcd for C17H20N4SO: C, 62.19; H, 6.09; N, 17.07; S, 9.75. Found: C, 62.33; H, 6.26; N, 17.32; S, 9.93.

5-[(Dimethylamino)methylene]-2-{[6-methoxy-3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-3-methylthiazolidin-4-one (5b)

Brown crystalline solid; yield 82%; mp 184–186°C; IR (cm-1): 1702 (C=O), 1567 (C=N), 1512 (C=C); 1H NMR: δ 1.88–1.95 (m, 2H, CH2), 2.79 (t, 2H, CH2, J = 6 Hz), 2.95 (t, 2H, CH2, J = 6 Hz), 3.16 (s, 6H, NMe2), 3.34 (s, 3H, NCH3), 3.82 (s, 3H, OCH3), 6.64 (d, 1H, C6H5, J = 2.6 Hz), 6.70 (dd, 1H, C6H5, J = 2.6 Hz, J = 7 Hz), 7.44 (s, 1H, =CH), 8.21 (d, 1H, C6H5, J = 7 Hz). Anal. Calcd for C18H22N4SO2: C, 60.33; H, 6.14; N, 15.64; S, 8.93. Found: C, 60.56; H, 6.33; N, 15.78; S, 9.12.

General procedure for the synthesis of 6

Compound 6 was obtained from compound 1 in one step or in two steps through the intermediary of compound 5. Method A: a mixture of enaminone 5 (1.0 mmol) and Lawesson’s reagent (1.0 mmol) in dry toluene (20 mL) was heated under reflux for 2 h. The solvent was removed under reduced pressure and the solid residue was crystallized from ethanol. Method B: a mixture of thiazolidin-4-one 1 (1.0 mmol) and Lawesson’s reagent (1.0 mmol) in dry toluene (15 mL) was heated under reflux for 2 h. Dimethylformamide-dimethylacetal (10 mmol) was then added and heating was continued for an additional 1 h. Excess solvent was removed under reduced pressure and the mixture was left overnight. The resultant solid was filtered and crystallized from ethanol.

2-{[3,4-Dihydronaphthalen-1(2H)-ylidene]hydrazono}-5-[(dimethylamino)methylene]-3-methylthiazolidine-4-thione (6a)

Grey crystals; yield 78%; mp 208–212°C; IR (cm-1): 1605 (C=N), 1489 (C=C), 1242 (C=S); 1H NMR: δ 1.93 (m, 2H, CH2), 2.83 (t, 2H, CH2, J = 7 Hz), 2.97 (t, 2H, CH2, J = 7 Hz), 3.30 (s, 6H, NMe2), 3.79 (s, 3H, N-CH3), 7.15 (m, 1H, C6H5), 7.22–7.28 (m, 2H, C6H5), 8.25 (s, 1H, =CH), 8.28 (dd, 1H, C6H5, J = 1.2 Hz, J = 7 Hz); MS: m/z 345 (M+H)+ (100%). Anal. Calcd for C17H20N4S2: C, 59.27; H, 5.85; N, 16.26; S, 18.62. Found: C, 59.42; H, 5.63; N, 16.39; S, 18.86.

5-[(Dimethylamino)methylene]-2-{[6-methoxy-3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-3-methylthiazolidine-4-thione (6b)

Brown crystals; yield 72%; mp 194–198°C; IR (cm-1): 1615 (C=N), 1518 (C=C), 1256 (C=S); 1H NMR: δ 1.96 (m, 2H, CH2), 2.86 (t, 2H, CH2, J = 6 Hz), 2.97 (t, 2H, CH2, J = 6 Hz), 3.20 (s, 6H, NMe2), 3.38 (s, 3H, NCH3), 3.89 (s, 3H, OCH3), 6.66 (d, 1H, C6H5, J = 3 Hz), 6.83 (dd, 1H, C6H5, J = 3 Hz, J = 6 Hz), 8.31–8.33 (d, 1H, C6H5, J = 6 Hz) 8.38 (s, 1H, =CH). Anal. Calcd for C18H22N4OS2: C, 57.72; H, 5.92; N, 14.96; S, 17.12. Found: C, 57.88; H, 6.12; N, 15.18; S, 17.27.

General procedure for the synthesis of 7a–f

A solution of phenylhydrazine hydrochloride (0.75 mmol) in ethanol (25 mL) was added dropwise with stirring to a solution of compound 6 (0.5 mmol) in ethanol (5 mL). After complete addition, the mixture was heated at 70–80°C for 5–6 h. The progress of reaction was monitored by TLC. The reaction mixture was then cooled to room temperature and the separated solid was filtered, dried, and crystallized from ethanol.

{[3,4-Dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-1-phenyl-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7a)

Orange solid; yield 45%; mp 148–150°C; IR (cm-1): 1582 (C=N), 1497 (C=C); 1H NMR: δ 1.97 (m, 2H, CH2), 2.86 (t, 2H, CH2, J = 7 Hz), 3.02 (t, 2H, CH2, J = 7 Hz), 3.50 (s, 3H, NCH3), 7.19 (d, 1H, C6H5, J = 7 Hz), 7.33 (m, 2H, C6H5), 7.53 (m, 3H, C6H5), 7.92 (m, 2H, C6H5), 8.23 (s, 1H, =CH), 8.35 (dd, 1H, C6H5, J = 2 Hz, J = 6 Hz); 13C NMR: δ 164.1, 164.0, 157.9 (C=N), 153, 141, 134, 132, 130, 129, 128, 126, 125, 123 (C6H5), 30.0, 29.7, 27.5, 27.2; MS: m/z 374 (M+H)+ (10%). Anal. Calcd For C21H19N5S: C, 67.56; H, 5.09; N, 18.76; S, 8.57. Found: C, 67.71; H, 5.25; N, 18.92; S, 8.76.

1-(4-Chlorophenyl)-5-{[3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7b)

Orange fluffy solid; yield 42%; mp 172–174°C; IR (cm-1): 1585 (C=N), 1501 (C=C); 1H NMR: δ 1.93–1.99 (m, 2H, CH2), 2.85 (t, 2H, CH2, J = 6 Hz), 3.01 (t, 2H, CH2, J = 6 Hz), 3.49 (s, 3H, NCH3), 7.19 (d, 1H, C6H5, J = 6 Hz), 7.28–7.36 (m, 2H, C6H5), 7.48 (m, 2H, C6H5), 7.83–7.87 (m, 2H, C6H5), 8.19 (s, 1H, =CH), 8.33 (dd, 1H, C6H5, J = 1.5 Hz, J = 6 Hz); 13C NMR: δ 166.0, 164.1, 157.7 (C=N), 151.5, 141.2, 138.5, 135.1, 132.2, 130.4, 129.5, 128.7, 126.4, 125.6, 124.6 (C6H5), 30.0, 29.8, 27.5, 22.2; MS: m/z 408 (M+H)+ (20%). Anal. Calcd for C21H18N5SCl: C, 61.91; H, 4.42; N, 17.19; S, 7.86. Found: C, 62.10; H, 4.66; N, 17.34; S, 8.01.

5-{[3,4-Dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-1-(o-tolyl)-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7c)

Bright orange solid; yield 38%; mp 158–160°C; IR (cm-1): 1580 (C=N), 1491 (C=C); 1H NMR: δ 1.93–1.99 (m, 2H, CH2), 2.74 (s, 3H, CH3), 2.85 (t, 2H, CH2, J = 6 Hz), 3.00 (t, 2H, CH2, J = 6 Hz), 3.49 (s, 3H, NCH3), 7.24 (d, 1H, C6H5, J = 1.5 Hz), 7.25–7.42 (m, 6H, Ar-H), 7.70 (d, 1H, C6H5, J = 7 Hz), 8.33 (dd, 1H, C6H5, J = 1.5 Hz, J = 6 Hz), 8.42 (s, 1H, =CH); 13C NMR: δ 166.4, 163.7, 159.0 (C=N), 151.5, 141.1, 140.5, 139.9, 132.5, 131.6, 130.3, 129.9, 128.7, 126.5, 125.6, 115.3 (Ar-C), 30.0, 29.6, 27.4, 22.2, 18.1; MS: m/z 388 (M+H)+ (100%). Anal. Calcd for C22H21N5S: C, 68.21; H, 5.42; N, 18.08; S, 8.26. Found: C, 68.44; H, 5.68; N, 18.25; S, 8.40.

5-{[6-methoxy-3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-1-phenyl-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7d)

Brown needles; yield 55%; mp 162–164°C; IR (cm-1): 1582 (C=N), 1494 (C=C); 1H NMR: δ 1.94–1.97 (m, 2H, CH2), 2.83 (t, 2H, CH2, J = 6 Hz), 2.99 (t, 2H, CH2, J = 6 Hz), 3.49 (s, 3H, NCH3), 3.86 (s, 3H, OCH3), 6.68 (d, 1H, C6H5, J = 2.5 Hz), 6.87 (dd, 1H, C6H5, J = 2.5 Hz, J = 6 Hz), 7.51–7.54 (m, 3H, C6H5), 7.91 (m, 2H, C6H5), 8.22 (s, 1H, =CH), 8.31 (d, 1H, C6H5, J = 8 Hz); 13C NMR: δ 166.1, 163.8, 161.3 (C=N), 156.9, 153.2, 143.1, 141.1, 134.8, 132.4, 129.2, 127.6, 125.2, 123.5, 113.2, 112.6 (Ar-C), 55.3, 30.3, 29.7, 27.4, 22.3; MS: m/z 404 (M+H)+ (10%). Anal. Calcd for C22H21N5SO: C, 65.50; H, 5.21; N, 17.36; S, 7.94. Found: C, 65.75; H, 5.41; N, 17.51; S, 8.16.

1-(4-Chlorophenyl)-5-{[6-methoxy-3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7e)

Light orange solid; yield 52%; mp 198–200°C; IR (cm-1): 1586 (C=N), 1496 (C=C); 1H NMR: δ 1.94–1.97 (m, 2H, CH2), 2.83 (t, 2H, CH2, J = 6 Hz), 2.98 (t, 2H, CH2, J = 6 Hz), 3.49 (s, 3H, NCH3), 3.85 (s, 3H, OCH3), 6.68 (s, 1H, C6H5), 6.87 (dd, 1H, C6H5, J = 2.6 Hz, J = 6 Hz), 7.47–7.50 (m, 2H, C6H5), 7.85 (m, 2H, C6H5), 8.20 (s, 1H, =CH), 8.29 (d, 1H, C6H5, J = 8 Hz); 13C NMR: δ 166.0, 163.9, 161.3 (C=N), 156.7, 151.5, 143.1, 141.1, 138.5, 135.3, 129.5, 127.6, 125.1, 124.6, 113.2, 112.7 (Ar-C), 55.3, 30.3, 29.8, 27.4, 22.3; MS: m/z 438 (M+H)+ (100%). Anal. Calcd for C22H20N5SOCl: C, 60.41; H, 4.57; N, 16.01; S, 7.32. Found: C, 60.64; H, 4.46; N, 16.25; S, 7.44.

5-{[6-Methoxy-3,4-dihydronaphthalen-1(2H)-ylidene]hydrazono}-6-methyl-1-(o-tolyl)-5,6-dihydro-1H-pyrazolo[3,4-d]thiazole (7f)

Light brown solid; yield 44%; mp 160–164°C; IR (cm-1): 1581 (C=N), 1490 (C=C); 1H NMR: δ 1.92–1.98 (m, 2H, CH2), 2.74 (s, 3H, CH3), 2.82 (t, 2H, CH2, J = 6 Hz), 2.99 (t, 2H, CH2, J = 6 Hz), 3.48 (s, 3H, NCH3), 3.85 (s, 3H, OCH3), 6.67 (s, 1H, C6H5), 6.85 (d, 1H, C6H5, J = 6 Hz) 7.35–7.42 (m, 2H, C6H5), 7.70 (d, 1H, C6H5, J = 8 Hz), 8.29 (d, 1H, C6H5, J = 8 Hz), 8.41 (s, 1H, =CH); 13C NMR: δ 166.4, 163.5, 161.3 (C=N), 157.9, 151.5, 143.0, 140.4, 139.8, 132.5, 131.6, 130.3, 127.5, 126.4, 115.4, 113.2, 112.6 (Ar-C), 55.3, 30.3, 29.6, 27.3, 22.3, 18.1; MS: m/z 406 (M+H)+ (50%). Anal. Calcd for C22H23N5SO: C, 65.18; H, 5.67; N, 17.28; S, 7.90. Found: C, 65.32; H, 5.76; N, 17.08; S, 7.78.


Corresponding author: R. P. Chaudhary, Sant Longowal Institute of Engineering and Technology, Department of Chemistry, Longowal (Sangrur), Punjab 148106, India, e-mail:

References

[1] Chang-Ji, Z.; Li-Li, X.; Liang-Peng, S.; Jing, M.; Hu-Ri, P. Synthesis and antibacterial activity of novel 1,3-diphenyl-1H-pyrazoles functionalized with phenylalanine-derived rhodanines. Eur. J. Med. Chem. 2012, 58, 112–116.Suche in Google Scholar

[2] Bakavoli, M.; Bagherzadeh, G.; Vaseghifar, M.; Shiri, A.; Pordel, M.; Mashreghi, M.; Pordeli, P.; Araghi, M. Molecular iodine promoted synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as potential antibacterial agents. Eur. J. Med. Chem.2010, 45, 647–650.Suche in Google Scholar

[3] Osama, I. El-S.; Mohamed, M. B.; Samy, M. I.; Christophe, P.; Graciela, A.; Robert, S. J. B.; Adel, A. R. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur. J. Med. Chem.2009, 44, 3746–3753.Suche in Google Scholar

[4] Aymn, E. R.; Mohamed, I. H.; Randa, E. A. M.; Jehan, A. M.; Farouk, M. E.; Abdel, M. Synthesis and antiviral evaluation of some new pyrazole and fused pyrazolopyrimidine derivatives. Bioorg. Med. Chem.2008, 16, 7102–7106.Suche in Google Scholar

[5] Sherif, A. F. R. Polysubstituted pyrazoles, part 6. Synthesis of some 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazol-3-carbonyl derivatives linked to nitrogenous heterocyclic ring systems as potential antitumor agents. Bioorg. Med. Chem.2010, 18, 2767–2776.Suche in Google Scholar

[6] Mohamed, R. S.; Tamer, S. S.; Abdelrahman, S. M.; Ahmed, M.; Ahmad, M. F. Synthesis and analgesic/anti-inflammatory evaluation of fused heterocyclic ring systems incorporating phenylsulfonyl moiety. Bioorg. Med. Chem.2008, 16, 6344–6352.Suche in Google Scholar

[7] Kuppusamy, S.; Gnanamani, S.; Nagarajan, P. S.; Seeralan, M.; Paramasivan, T. P.; Melani, R. Synthesis and antiviral activity of 4,4′-(arylmethylene)bis(1H-pyrazol-5-ols) against peste des petits ruminant virus (PPRV). Bioorg. Med. Chem. Lett.2009, 19, 4501–4503.Suche in Google Scholar

[8] Stein, R. G.; Beil, J. H.; Singh, T. Antimalarials. 4-Substituted 1H-pyrazolo[3,4-b]quinolines. J. Med. Chem.1970, 13, 153–155.Suche in Google Scholar

[9] Michael, S.; Christodoulou, S. L.; Konstantinos, M. K.; Serkos, A. H. Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity. Bioorg. Med. Chem. 2010, 18, 4338–4350.Suche in Google Scholar

[10] Taylor, E. C.; Patel, H.; Kumar, H. Synthesis of pyrazolo 3,4-dipyrimidine analogues of the potent agent N4-(2-amino-4-3H-oxo-7H-pyrrolo-2,3-dipyrimidin-5-yl)ethylbenzoyl-L-glutamic acid (LY231514). Tetrahedron1992, 48, 8089–8100.Suche in Google Scholar

[11] Khobragade, C. N.; Bodade, R. G.; Dawane, B. S.; Konda, S, G.; Khandare, N. T. Synthesis and biological activity of pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidin-4-one derivatives: in silico approach. J. Enzyme Inhib. Med. Chem.2010, 25, 615–621.Suche in Google Scholar

[12] Wedad, M. Al-A.; Tahir, M. I. M.; Siti-Noor-Adnalizawati, A.; Siti, F. H.; Nazlina, I.; Yaacob, W. A. Synthesis, antibacterial activity and cytotoxicity of new fused pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives from new 5-aminopyrazoles. Eur. J. Med. Chem.2013, 64, 464–476.Suche in Google Scholar

[13] Gautam, D.; Gautam, P.; Chaudhary, R. P. N-Methylpyridinium tosylate catalysed green and efficient synthesis of some novel 2,4-disubstituted thiazoles and 4-thiazolidinones. Chin. Chem. Lett.2012, 23, 1221–1224.Suche in Google Scholar

[14] Gupta, R.; Chaudhary, R. P. X-ray, NMR and DFT studies on benzo[h]thiazolo[2,3-b]quinazoline derivatives. J. Mol. Struct.2013, 1049, 189–197.Suche in Google Scholar

[15] Gautam, D.; Gautam, P.; Chaudhary, R. P. Expedient and green synthesis of some novel 4-thiazolidinones and new 2,4-disubstituted thiazoles with tetrahydrocarbazole pendant. Lett. Org. Chem. 2012, 9, 660–663.Suche in Google Scholar

[16] Sahu, S. K.; Mishra, S. K.; Mohanta, R. K.; Pattanayak, S. P.; Panda, C. S. Synthesis and antibacterial activity of 2-(2,4-dinitrophenyl)-3,5-diphenyl (substituted)-6-aryl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d] thiazoles. Indian J. Pharm. Sci.2006, 68, 377–380.Suche in Google Scholar

[17] Rajanarendar, E.; Afzal, M.; Karunakar, D. Synthesis of isoxazolylpyrazolo[3,4-d]thiazoles and isoxazolylthiazoles and their antibacterial and antifungal activity. Indian J. Chem. B.2004, 43B, 168–173.Suche in Google Scholar

[18] Gautam, D.; Gautam, P.; Chaudhary, R. P. Efficient synthesis of 2,4-disubstituted thiazoles and 2-substituted 4-thiazolidinones under solvent free conditions. Heterocycl. Commun.2011, 17, 147–150.Suche in Google Scholar

[19] Waganat, W. W.; Elkholy, Y. E. One-pot synthesis of thiazoles from pyridazin-3-hydrazidic acid derivatives. Phosphor. Sulf. Silicon Relat. Elem.2002, 177, 2661–2673.Suche in Google Scholar

[20] Abdel-Sayed, N. I. Novel synthesis of new symmetrical bis-heterocyclic compounds: synthesis of bis-thiazolo, bis-pyrazolo-, bis-benzotriazolo, bis-indolo- and bis-pyrazolyl thiazolo-2,6-diaminopyridine derivatives. Bulg. Chem. Commun. 2010, 42, 20–26.Suche in Google Scholar

[21] Waganat, W. W.; Fleita, D. H.; Mohareb, R. M. Reaction of 4-aryl-3-thiosemicarbazides with phenylisothiocyanate: a facile synthesis of thiazole, pyrazole and pyrimidine derivatives. J. Chin. Chem. Soc.1999, 46, 97–104.Suche in Google Scholar

[22] Mohareb, R. M.; Zohdi, H. F.; Wardakhan, W. W. Reaction of 3-phenyl-5-aminopyrazole with carbon disulfide: a novel synthesis of 3-(3′-phenylpyrazol-5′-yl)-4-phenylpyrazol-2-thione as well as of pyrazolo[3,4-d]thiazole and pyrano[2,3-d]thiazole derivatives. Monatsh. Chem. 1995, 126, 1391–1400.Suche in Google Scholar

[23] Pelletier, S.; Pinson, B.; Smejkal, T.; Lamberth, C. A general synthesis of tetrahydropyrazolo[3,4-d]thiazoles. Tetrahedron2013, 69, 4641–4651.Suche in Google Scholar

[24] Tumul, S.; Anil, K. G.; Wahajul, H.; Sudhir, S.; Setu, B. K. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. ARKIVOC2005, ii, 120–130.10.3998/ark.5550190.0006.209Suche in Google Scholar

Received: 2014-1-12
Accepted: 2014-3-31
Published Online: 2014-6-14
Published in Print: 2014-8-1

©2014 by De Gruyter

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Heruntergeladen am 23.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hc-2014-0007/html
Button zum nach oben scrollen